SK invests in Standigm for AI-based drug development

Updated:

HONG KONG – SK Holdings Co. Ltd. invested KRW10 billion (US$8.6 million) in Standigm Inc., an artificial intelligence (AI)-powered biotech company based in Seoul, Korea. It is the second big investment Standigm has attracted this year after a KRW13 billion series B round in March.

Read more in English press

Bioworld

Tags: Investment , Standigm

Categories: News